Ani Pharmaceuticals (ANIP) Accumulated Expenses (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Accumulated Expenses data on file, last reported at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 38.4% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 38.4% YoY), and the FY2025 full-year result was $37.9 million, changed 0.46% from the prior year.
• Accumulated Expenses fell to $13.7 million in Q1 2026, from $37.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $37.9 million in Q4 2025 to a low of $4.8 million in Q1 2023.
• A 5-year average of $15.5 million and a median of $11.5 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 53.6% in 2023 and jumped 469.57% in 2024, its largest moves.
• Tracing ANIP's Accumulated Expenses over 5 years: stood at $10.3 million in 2022, then jumped by 130.66% to $23.8 million in 2023, then soared by 58.6% to $37.7 million in 2024, then gained by 0.46% to $37.9 million in 2025, then sank by 63.76% to $13.7 million in 2026.
• Business Quant data shows ANIP's Accumulated Expenses at $13.7 million in Q1 2026, $37.9 million in Q4 2025, and $14.0 million in Q3 2025.